anonymous
Guest
anonymous
Guest
It seems the Alzheimers data has dominated the earnings ! And SPINRAZA as expected contributing much to revenues. https://news.alphastreet.com/biogen-stock-gains-on-upbeat-q2-results/
Too bad the Alzheimer's data is all smoke and mirrors.